Results 51 to 60 of about 3,726 (180)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatology and Therapy, 2023
Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation.
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. Feldman   +6 more
doaj   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

International Journal of Dermatology, EarlyView.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini, Carlo Alberto Maronese, Federica Derlino, Giovanni Genovese, Chiara Moltrasio, Luisa Sarno, Stefano Buffon, Bianca Cei, Giammarco Granieri, Valentina Dini, Marco Romanelli, Vincenzo Maione, Stefano Bighetti, Marina Venturini, Edoardo Cammarata, Paola Savoia, Antonio Di Guardo, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Lorenza Burzi, Claudia Leporati, Nunzia Di Cristo, Nicola Zerbinati, Alex G. Ortega‐Loayza, Angelo Valerio Marzano   +25 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open
Objectives To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase ...
Iain B McInnes, Laura C Coates, Philipp Sewerin, Frédéric Lavie, Mohamed Sharaf, Miriam Zimmermann, Michela Efficace   +6 more
doaj   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source